David Trainor 1 , Lois Evans 1 , Rupert Bird 2 Show Affiliations »
Abstract
OBJECTIVES: A single case report on cannabinoid treatment for treatment-resistant Tourette syndrome (TS). METHOD: Our subject received 10.8 mg Tetrahydocannabinol and 10 mg cannabidiol daily, in the form of two oro-mucosal sprays of 'Sativex®', twice daily. Assessment was pre-treatment and at week one, two, and four during treatment. He completed the Yale Global Tic Severity Scale as a subjective measure, and was videoed at each stage. The videos were objectively rated by two assessors, blind to the stage of treatment, using the Original Rush Videotape Rating Scale. RESULTS: Both subjective and objective measures demonstrated marked improvement in the frequency and severity of motor and vocal tics post-treatment. There was good interrater reliability of results. CONCLUSIONS: Our results support previous research suggesting that cannabinoids are a safe and effective treatment for TS and should be considered in treatment-resistant cases. Further studies are needed to substantiate our findings. © The Royal Australian and New Zealand College of Psychiatrists 2016.
OBJECTIVES: A single case report on cannabinoid treatment for treatment-resistant Tourette syndrome (TS ). METHOD: Our subject received 10.8 mg Tetrahydocannabinol and 10 mg cannabidiol daily, in the form of two oro-mucosal sprays of 'Sativex®', twice daily. Assessment was pre-treatment and at week one, two, and four during treatment. He completed the Yale Global Tic Severity Scale as a subjective measure, and was videoed at each stage. The videos were objectively rated by two assessors, blind to the stage of treatment, using the Original Rush Videotape Rating Scale. RESULTS: Both subjective and objective measures demonstrated marked improvement in the frequency and severity of motor and vocal tics post-treatment. There was good interrater reliability of results. CONCLUSIONS: Our results support previous research suggesting that cannabinoids are a safe and effective treatment for TS and should be considered in treatment-resistant cases. Further studies are needed to substantiate our findings. © The Royal Australian and New Zealand College of Psychiatrists 2016.
Entities: Chemical
Disease
Keywords:
Sativex®; Tetrahydrocannabinol; cannabis; tourette syndrome
Mesh： See more »
Substances： See more »
Year: 2016
PMID： 27558217 DOI： 10.1177/1039856216663737
Source DB: PubMed Journal: Australas Psychiatry ISSN： 1039-8562 Impact factor: 1.369